ArticlePediatric surgery international2025
Sclerotherapy as first-line treatment of rectal prolapse in children, including those with anorectal malformations.
Article in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of injection sclerotherapy in the management of reducible rectal prolapse (RP) in children.
methodsChildren with reducible RP who underwent sclerotherapy with Kinurea-H
resultsThirty-two patients were included, 18 FRP and 14 ORP (7 anorectal malformation (ARM), 2 anorexia nervosa, 1 Hirschsprung disease, 2 spinal dysraphism, 1 Ehlers-Danlos, 1 short bowel syndrome) with a median age of 4 years. After one injection, the success rate was higher in FRP (78%) than in ORP (21%) (p = 0.0009). After 2-4 injections, success rate was 94% in FRP and 93% in ORP, with a minimal mucosal resection of the fixed portion (less than 5 mm, limited to the ano-cutaneous junction) in 4/7 ARM. Repeated injections were performed at same site in all ORP without ARM, and in only 43% of ORP with ARM. Recurrence of reducible RP after the first injection at one site was associated with ORP (p = 0.03), particularly in ORP without ARM (p = 0.06).
conclusionSclerotherapy for reducible RP is efficient after failure of conservative management in FRP and success rate after repeated injections is encouraging in ORP, particularly in ARM.
Indexed as
Identifiers
41455084What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.